Bookmark
Forward
Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381.
Drugs in R&D 2010Sizes of these terms reflect their relevance to your search.
Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This review discusses the development history and scientific profile of this new compound.
Citation
Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381. Drugs in R&D. 2010;10(1):33-6
Mesh Tags
Substances
PMID: 20509713
View Full Text
